UB Paderborn / Katalog / Suche / in CDI

Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics

Clinical pharmacokinetics, 2018-08, Vol.57 (8), p.911-928

2018

Volltextzugriff (PDF)

Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug–Drug Interactions

Clinical pharmacokinetics, 2015-12, Vol.54 (12), p.1205-1222

2015

Volltextzugriff (PDF)

The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor

Antiviral therapy, 2015, Vol.20 (1), p.29-37

2015

Volltextzugriff (PDF)

Effects of rimegepant 75 mg daily on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female participants

Headache, 2023-05, Vol.63 (5), p.652-662

2023

Volltextzugriff (PDF)

An Open-Label Investigation into Drug–Drug Interactions Between Multiple Doses of Daclatasvir and Single-Dose Cyclosporine or Tacrolimus in Healthy Subjects

Clinical drug investigation, 2015-05, Vol.35 (5), p.281-289

2015

Volltextzugriff (PDF)

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

Clinical pharmacokinetics, 1997-03, Vol.32 (3), p.210-258

1997

Volltextzugriff (PDF)

Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529

Antimicrobial agents and chemotherapy, 2016-05, Vol.60 (5), p.2782-2789

2016

Volltextzugriff (PDF)

CYP2C19 Genotype–Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir‐Boosted Atazanavir in Healthy Subjects

Journal of clinical pharmacology, 2017-02, Vol.57 (2), p.235-246

2017

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of Atazanavir-containing Antiretroviral Regimens, with or without Ritonavir, in Patients who are HIV-positive and Treatment-naïve

Pharmacotherapy, 2013-03, Vol.33 (3), p.284-294

2013

Volltextzugriff (PDF)

Single- and multiple-ascending dose studies to evaluate the safety, tolerability, and pharmacokinetics of daclatasvir and asunaprevir in healthy male Japanese subjects

International journal of clinical pharmacology and therapeutics, 2015-04, Vol.53 (4), p.292

2015

Volltextzugriff (PDF)

Gilbert Syndrome and the Development of Antiretroviral Therapy–Associated Hyperbilirubinemia: Genetic Screening Is Unnecessary

The Journal of infectious diseases, 2006-06, Vol.193 (11), p.1611-1612

2006

Volltextzugriff (PDF)

Asunaprevir: An HCV Protease Inhibitor With Preferential Liver Distribution

Clinical pharmacology in drug development, 2017-03, Vol.6 (2), p.195-200

2017

Volltextzugriff (PDF)

Protein binding in antiretroviral therapies

AIDS research and human retroviruses, 2003-09, Vol.19 (9), p.825-835

2003

Volltextzugriff (PDF)

Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction

Journal of acquired immune deficiency syndromes (1999), 2004-08, Vol.36 (5), p.1034

2004

Volltextzugriff (PDF)

Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children

The Pediatric infectious disease journal, 2003-03, Vol.22 (3), p.216-223

2003

Volltextzugriff (PDF)

Pharmacokinetics of the NS3 Protease Inhibitor, Asunaprevir (ASV, BMS-650032), in Phase I Studies in Subjects With or Without Chronic Hepatitis C

Clinical pharmacology in drug development, 2013-10, Vol.2 (4), p.316-327

2013

Volltextzugriff (PDF)

Effects of rimegepant 75mg daily on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female participants

Headache, 2023-05, Vol.63 (5), p.652-662

2023

Volltextzugriff (PDF)

Quantitative Systems Pharmacology can reduce attrition and improve productivity in pharmaceutical research and development

Frontiers in pharmacology, 2014-11, Vol.5, p.247-247

2014

Volltextzugriff (PDF)

Ritonavir : Clinical pharmacokinetics and interactions with other anti-HIV agents

Clinical pharmacokinetics, 1998-10, Vol.35 (4), p.275-291

1998

Volltextzugriff (PDF)

Alprazolam in young and elderly men: sensitivity and tolerance to psychomotor, sedative and memory effects

The Journal of pharmacology and experimental therapeutics, 1997-06, Vol.281 (3), p.1317

1997

Volltextzugriff (PDF)

Triazolam pharmacokinetics after intravenous, oral, and sublingual administration

Journal of clinical psychopharmacology, 1995-08, Vol.15 (4), p.259-262

1995

Volltextzugriff (PDF)

CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects: The Journal of Clinical Pharmacology / Vol XX No X 2016

Journal of clinical pharmacology, 2017-02, Vol.57 (2), p.235-246

2017

Volltextzugriff (PDF)

Gilbert Syndrome and the Development of Antiretroviral Therapy-Associated Hyperbilirubinemia: Genetic Screening Is Unnecessary/Reply to Nettles et al

The Journal of infectious diseases, 2006-06, Vol.193 (11), p.1611

2006

Volltextzugriff (PDF)

The Effect of Ritonavir on the Pharmacokinetics of Meperidine and Normeperidine

Pharmacotherapy, 2000-05, Vol.20 (5), p.549-553

2000

Volltextzugriff (PDF)

Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics

Pharmacogenetics (London), 2004-05, Vol.14 (5), p.279-284

2004

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics

Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug–Drug Interactions

The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor

Effects of rimegepant 75 mg daily on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female participants

An Open-Label Investigation into Drug–Drug Interactions Between Multiple Doses of Daclatasvir and Single-Dose Cyclosporine or Tacrolimus in Healthy Subjects

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529

CYP2C19 Genotype–Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir‐Boosted Atazanavir in Healthy Subjects

Pharmacokinetics and Pharmacodynamics of Atazanavir-containing Antiretroviral Regimens, with or without Ritonavir, in Patients who are HIV-positive and Treatment-naïve

Single- and multiple-ascending dose studies to evaluate the safety, tolerability, and pharmacokinetics of daclatasvir and asunaprevir in healthy male Japanese subjects

Gilbert Syndrome and the Development of Antiretroviral Therapy–Associated Hyperbilirubinemia: Genetic Screening Is Unnecessary

Asunaprevir: An HCV Protease Inhibitor With Preferential Liver Distribution

Protein binding in antiretroviral therapies

Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction

Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children

Pharmacokinetics of the NS3 Protease Inhibitor, Asunaprevir (ASV, BMS-650032), in Phase I Studies in Subjects With or Without Chronic Hepatitis C

Effects of rimegepant 75mg daily on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female participants

Quantitative Systems Pharmacology can reduce attrition and improve productivity in pharmaceutical research and development

Ritonavir : Clinical pharmacokinetics and interactions with other anti-HIV agents

Alprazolam in young and elderly men: sensitivity and tolerance to psychomotor, sedative and memory effects

Triazolam pharmacokinetics after intravenous, oral, and sublingual administration

CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects: The Journal of Clinical Pharmacology / Vol XX No X 2016

Gilbert Syndrome and the Development of Antiretroviral Therapy-Associated Hyperbilirubinemia: Genetic Screening Is Unnecessary/Reply to Nettles et al

The Effect of Ritonavir on the Pharmacokinetics of Meperidine and Normeperidine

Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics

Suchergebnisse filtern